TUBOCURARINE CHLORIDE

US Previously Marketed

First approved in 1945

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C37H41N2O6.Cl.ClH.5H2O
Molecular Weight	771.722
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.O.O.O.Cl.[Cl-].COC1=CC2=C3[C@@H](CC4=CC=C(O)C(OC5=C(OC)C=C6CCN(C)[C@@H](CC7=CC=C(OC3=C1O)C=C7)C6=C5)=C4)[N+](C)(C)CC2

InChI

InChIKey=WMIZITXEJNQAQK-GGDSLZADSA-N

InChI=1S/C37H40N2O6.2ClH.5H2O/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33;;;;;;;/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41);2*1H;5*1H2/t28-,29+;;;;;;;/m0......./s1

HIDE SMILES / InChI

Molecular Formula	C37H41N2O6
Molecular Weight	609.7312
Charge	1
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry
Defined Stereocenters	2 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://howmed.net/pharmacology/tubocurarine-non-depolarizing-neuromuscular-blocker/ | https://www.drugbank.ca/drugs/DB01199

Tubocurarine, a naturally occurring alkaloid, is used to treat smoking withdrawl syndrom. Tubocurarine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis of Tubocurarine's positively reinforcing properties. A stimulating effect is exerted mainly in the cortex via the locus ceruleus and a reward effect is exerted in the limbic system. At low doses the stimulant effects predominate while at high doses the reward effects predominate. Intermittent intravenous administration of Tubocurarine activates neurohormonal pathways, releasing acetylcholine, norepinephrine, dopamine, serotonin, vasopressin, beta-endorphin, growth hormone, and ACTH. Tubocurarine competes with acetylcholine for post-synaptic nicotinic NM receptors and blocks them.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Neuronal acetylcholine receptor; alpha3/beta4 40 Target ID: CHEMBL1907594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15203153	Antagonist 2849	2.0 µM [IC50]
Neuronal acetylcholine receptor; alpha4/beta2 77 Target ID: CHEMBL1907589 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23757208	Antagonist 2849	9.2 µM [IC50]
Neuronal acetylcholine receptor subunit alpha-2 3 Target ID: Q15822 Gene ID: 1135.0 Gene Symbol: CHRNA2 Target Organism: Homo sapiens (Human) Sources: https://www.drugbank.ca/drugs/DB01199 \| https://www.ncbi.nlm.nih.gov/pubmed/11562442	Antagonist 2849
Muscle-type nicotinic acetylcholine receptor 65 Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18633030	Antagonist 2849	24.0 nM [IC50]
Serotonin 3a (5-HT3a) receptor 48 Target ID: CHEMBL1899 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7790853 \| https://www.ncbi.nlm.nih.gov/pubmed/9680250	Antagonist 2849	84.1 nM [Ki]
Small conductance calcium-activated potassium channel protein 1 5 Target ID: CHEMBL2369 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9287325 \| https://www.ncbi.nlm.nih.gov/pubmed/8781233	Blocker 555	27.0 µM [IC50]
Small conductance calcium-activated potassium channel protein 2 4 Target ID: CHEMBL4469 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10696100	Blocker 555	17.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Myasthenia gravis 21 Sources: http://www.druginfosys.com/drug.aspx?drugcode=742&type=1 https://www.drugs.com/mmx/tubocurarine-chloride.html	Diagnostic		Approved 8583	TUBOCURARINE CHLORIDE Approved Use Tubocurarine is indicated as a diagnostic aid for myasthenia gravis when the results of tests with neostigmine or edrophonium are inconclusive Launch Date 1945

C_max

Value	Dose	Co-administered	Analyte	Population
1.173 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7114542/	16 μg/kg/min other, intravenous dose: 16 μg/kg/min route of administration: Intravenous experiment type: OTHER co-administered:		TUBOCURARINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
117 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7114542/	16 μg/kg/min other, intravenous dose: 16 μg/kg/min route of administration: Intravenous experiment type: OTHER co-administered:		TUBOCURARINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
89 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7114542/	16 μg/kg/min other, intravenous dose: 16 μg/kg/min route of administration: Intravenous experiment type: OTHER co-administered:		TUBOCURARINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 620 OCT2 779 MATE1 415 MATE2 267 BSEP 550 MRP2 499 MRP3 246 MRP4 290 CYP1A2 2153 CYP2A6 879 CYP2C19 2057 CYP2E1 1060 OATP1B1 1079 OATP1B3 961	OCT1 393 OCT2 434

Drug as perpetrator

Target	Modality	Activity
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19833842/, https://pubmed.ncbi.nlm.nih.gov/23241029/, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50424714	likely [IC50 >100 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE2ODcifX0%3D	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE2ODcifX0%3D	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE2ODcifX0%3D	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE2ODcifX0%3D	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTY4NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE2ODcifX0%3D	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTY4NyJ9fQ%3D%3D	no [IC50 >10 uM]
BSEP 554	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50424714	yes [IC50 133 uM]
MRP2 625	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50424714	yes [IC50 133 uM]
MRP3 326	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50424714	yes [IC50 133 uM]
MATE2 267	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23241029/, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50424714	yes [IC50 55.5 uM]
OCT1 656	inhibitor 4027 Sources: https://transportal.compbio.ucsf.edu/compounds/tubocurarine/, https://pubmed.ncbi.nlm.nih.gov/19833842/	yes [IC50 62.4 uM]
MATE1 416	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23241029/, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50424714	yes [IC50 9.4 uM]
MRP4 345	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50424714	yes [IC50 9.6 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE2ODcifX0%3D	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE2ODcifX0%3D	yes [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
OCT1 393	substrate 4014 Sources: https://go.drugbank.com/drugs/DB01199, https://pubmed.ncbi.nlm.nih.gov/23984399/	yes
OCT2 434	substrate 4014 Sources: https://go.drugbank.com/drugs/DB01199, https://pubmed.ncbi.nlm.nih.gov/9260930/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTY4NyJ9fQ%3D%3D

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:9774	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9774
ZINC	ZINC000003978083	http://zinc15.docking.org/substances/ZINC000003978083

PubMed

Title	Date	PubMed
Monitoring neuronal calcium signalling using a new method for ratiometric confocal calcium imaging.	2003-09	12887977
GABAergic systems modulate nicotinic receptor-mediated seizures in mice.	2003-09	12829730
Curariform antagonists bind in different orientations to the nicotinic receptor ligand binding domain.	2003-08-22	12799358
Blockade of neuronal facilitatory nicotinic receptors containing alpha 3 beta 2 subunits contribute to tetanic fade in the rat isolated diaphragm.	2003-08	12740863
4-Aminopyridine inhibits the neuromuscular effects of nitric oxide and 8-Br-cGMP.	2003-07	12845382
Neuromuscular transmission of pectoral fin muscles of the goldfish Carassius auratus.	2003-07	12829051
Curariform antagonists bind in different orientations to acetylcholine-binding protein.	2003-06-20	12682067
Dopaminergic excitation of the goat carotid body is mediated by the serotonin type 3 receptor subtype.	2003-06-12	12809794
Pharmacological characterization of recombinant bovine alpha3beta4 neuronal nicotinic receptors stably expressed in HEK 293 cells.	2003-06-12	12770692
Screening procedure for eight quaternary nitrogen muscle relaxants in blood by high-performance liquid chromatography-electrospray ionization mass spectrometry.	2003-06-05	12726849
Neuromuscular effects of candoxin, a novel toxin from the venom of the Malayan krait (Bungarus candidus).	2003-06	12813007
Nicotine modulates the expression of a diverse set of genes in the neuronal SH-SY5Y cell line.	2003-05-02	12588870
Differential modulation of light-evoked on- and off-EPSCs by paired-pulse stimulation in salamander retinal ganglion cells.	2003-03-28	12650984
Task-dependent presynaptic inhibition.	2003-03-01	12629193
Chronic intraperitoneal endotoxin treatment in rats induces resistance to d-tubocurarine, but does not produce up-regulation of acetylcholine receptors.	2003-03	12648201
Bisindole alkaloids from Strychnos guianensis are effective antagonists of nicotinic acetylcholine receptors in cultured human TE671 cells.	2003-03	12644897
D-tubocurarine reduces GABA responses in rat substantia nigra dopamine neurons.	2003-03	12494406
A comparison of tubocurarine, rocuronium, and cisatracurium in the prevention and reduction of succinylcholine-induced muscle fasciculations.	2003-02	12776646
A novel class of ligand-gated ion channel is activated by Zn2+.	2003-01-10	12381728
Nicotinic activation of reticulospinal cells involved in the control of swimming in lampreys.	2003-01	12534977
Comparative fading responses induced by mivacurium, cisatracurium, and d-tubocurarine in the evoked muscular compound action potentials of the cat.	2003	12903920
Characterization of an apamin-sensitive potassium current in suprachiasmatic nucleus neurons.	2003	12849741
Synthesis and biological evaluation of 16 beta-pyrrolidinosteroidal derivatives.	2003	12642961
Impairment of synaptic vesicle exocytosis and recycling during neuromuscular weakness produced in mice by 2,4-dithiobiuret.	2002-12	12466444
Mechanism of nicotine-evoked release of 3H-noradrenaline in human cerebral cortex slices.	2002-12	12429579
Orientation of d-tubocurarine in the muscle nicotinic acetylcholine receptor-binding site.	2002-11-01	12196523
Synthesis and neuromuscular blocking activity of 16beta-N-methylpiperazino steroidal derivatives.	2002-11	12446049
Nicotinic receptors regulate the release of glycine onto lamina X neurones of the rat spinal cord.	2002-11	12423674
Sex difference in urethral response to electrical stimulation of efferent nerves in the pudendal sensory branch of rats.	2002-10	12445238
Pharmacology of nicotinic receptors in preBötzinger complex that mediate modulation of respiratory pattern.	2002-10	12364511
Nicotinic alpha 7 receptor clusters on hippocampal GABAergic neurons: regulation by synaptic activity and neurotrophins.	2002-09-15	12223543
Effects of nicotine exposure on T cell development in fetal thymus organ culture: arrest of T cell maturation.	2002-09-15	12218105
Interaction of d-tubocurarine analogs with mutant 5-HT(3) receptors.	2002-09	12243766
Neuromuscular action of Bothrops lanceolatus (Fer de lance) venom and a caseinolytic fraction.	2002-09	12220713
Electrophysiological analysis of synaptic transmission in central neurons of Drosophila larvae.	2002-08	12163536
Characterization of the interactions between volatile anesthetics and neuromuscular blockers at the muscle nicotinic acetylcholine receptor.	2002-08	12145052
Expression of soluble ligand- and antibody-binding extracellular domain of human muscle acetylcholine receptor alpha subunit in yeast Pichia pastoris. Role of glycosylation in alpha-bungarotoxin binding.	2002-07-26	12015305
Modulation by nicotine of the ionic currents in guinea pig ventricular cardiomyocytes. Relatively higher sensitivity to IKr and IKl.	2002-07	12616991
New evidence for a presynaptic action of prednisolone at neuromuscular junctions.	2002-07	12115947
Characterization of [(125) I]epibatidine binding and nicotinic agonist-mediated (86) Rb(+) efflux in interpeduncular nucleus and inferior colliculus of beta2 null mutant mice.	2002-06	12065623
Properties of nicotinic receptors underlying Renshaw cell excitation by alpha-motor neurons in neonatal rat spinal cord.	2002-06	12037212
Acetylcholine increases intracellular Ca2+ in taste cells via activation of muscarinic receptors.	2002-06	12037167
Nicotine increases hepatic oxygen uptake in the isolated perfused rat liver by inhibiting glycolysis.	2002-06	12023521
Effect of glycine on synaptic transmission at the third order giant synapse of the squids Alloteuthis subulata and Loligo vulgaris.	2002-05-31	12023063
Fm1-43 reveals membrane recycling in adult inner hair cells of the mammalian cochlea.	2002-05-15	12019313
Adenosine depresses a Ca(2+)-independent step in transmitter exocytosis at frog motor nerve terminals.	2002-04	11994123
Evaluation of the cholinomimetic actions of trimethylsulfonium, a compound present in the midgut gland of the sea hare Aplysia brasiliana (Gastropoda, Opisthobranchia).	2002-04	11960200
The nature of the acetylcholine and 5-hydroxytryptamine receptors in buccal smooth muscle of the pest slug Deroceras reticulatum.	2002-04	11919705
Peripheral site ligands accelerate inhibition of acetylcholinesterase by neutral organophosphates.	2001-12	11920914
Ketamine-pancuronium-narcotic technic for cardiovascular surgery in infants--a comparative study.	1975-11-01	1239221

Patents

Sample Use Guides

In Vivo Use Guide

Diagnostic aid (myasthenia gravis) Intravenous, 4 to 33 mcg (0.004 to 0.033 mg) per kg of body weight. Note: It is recommended that the test be terminated within two to three minutes by intravenous injection of 1.5 mg of neostigmine, since the marked exaggeration of myasthenia gravis symptoms may result in prolonged respiratory paralysis.

Route of Administration: Intravenous

In Vitro Use Guide

D-tubocurarine (30 uM), but not alpha-bungarotoxin (alpha-BTX, 0.1 uM), attenuated the nicotine (NIC) (100 uM)-evoked release of 3H-NA.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:34:35 GMT 2025` Edited by `admin` on `Mon Mar 31 17:34:35 GMT 2025`
Record UNII	900961Z8VR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TUBAINE

Preferred Name

English

TUBOCURARINE CHLORIDE

Official Name

English

TUBOCURARINE CHLORIDE HYDROCHLORIDE HYDRATE

Common Name

English

TUBOCURARINE CHLORIDE PENTAHYDRATE

Common Name

English

TUBOCURARINE CHLORIDE HYDROCHLORIDE HYDRATE [JAN]

Common Name

English

TUBOCURARINI CHLORIDUM [WHO-IP LATIN]

Common Name

English

NSC-757362

Code

English

TUBARINE PENTAHYDRATE

Common Name

English

D-TUBOCURARINE DICHLORIDE PENTAHYDRATE

Common Name

English

TUBOCURARINE CHLORIDE [MART.]

Common Name

English

TUBOCURARINE CHLORIDE [USP-RS]

Common Name

English

TUBOCURARINE CHLORIDE [USP MONOGRAPH]

Common Name

English

TUBOCURARINE CHLORIDE [ORANGE BOOK]

Common Name

English

(+)-TUBOCURARINE CHLORIDE HYDROCHLORIDE PENTAHYDRATE

Common Name

English

CURARE [HPUS]

Common Name

English

TUBOCURARINE CHLORIDE [VANDF]

Common Name

English

(+)-TUBOCURARINE CHLORIDE HYDROCHLORIDE, PENTAHYDRATE [WHO-IP]

Common Name

English

TUBOCURARANIUM, 7',12'-DIHYDROXY-6,6'-DIMETHOXY-2,2',2'-TRIMETHYL-, CHLORIDE, HYDROCHLORIDE, PENTAHYDRATE

Common Name

English

TUBOCURARINE CHLORIDE [WHO-IP]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29696